Shots:

• The first patient has been treated as a part of the global clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe COVID-19. The P-II/III clinical program has initiated in Italy- Spain- Germany- France- Canada and Russia and is enrolling patients instantly
• The study outside the US will assess the safety and efficacy of Kevzara (IV) + SOC vs PBO + SOC and is anticipated to enroll ~300 patients with Regeneron leading US studies and Sanofi leading ex-US studies
• Kevzara is a mAb inhibiting IL-6 pathway by targeting the IL-6 receptor- currently approved in multiple countries for patients with RA- who have not responded to or tolerated previous therapy

Click here to­ read full press release/ article | Ref: Sanofi | Image: DigitalMax